Home Suppliers Synterex, Inc. Featured Content (White Paper) This One’s for the Children: Progress in Pediatric Drug Development in the United States

Back

No Feature content logo

(White Paper) This One’s for the Children: Progress in Pediatric Drug Development in the United States

Posted by
Elizabeth

270 days ago

Prior to the FD&C Act, pharmaceutical companies were not required to provide proof of drug safety or a disclosure of all active ingredients. Since then, all new drugs undergo an intensive review process by the Food and Drug Administration (FDA), and ever-evolving guidance and regulations ensure that both new drugs and those with updated characteristics, such as dosing, delivery, and expanded indications, are safe and effective for the intended populations. A gap remains, however, for drug investigations including and targeted for children of varying ages.

Download and read now for more insights!

Show More

Get Your Copy

Please fill out the required information.

First Name is required.
Last Name is required.
Business Email is required.
Job Title is required.
Company Name is required.